Ajanta Pharma Limited (NSE: AJANTPHARM) clears resistance, moves up 5% intraday

Ajanta Pharma Limited (AJANTPHARM) breaks out, gaining +5% to ₹3352.0 on the NSE on 29 Jun 2026. The stock cleared its 6M resistance trendline, which was previously approaching resistance at ₹3115. Ajanta Pharma, a prominent player in the healthcare sector under drug manufacturers – specialty & generic, saw this move driven by its breakout above resistance. This indicates a potential shift in market sentiment, though it remains to be seen if this is a broader sector momentum or company-specific news.

Technical setup — trendlines & DMA

The current trendline structure shows a robust position for Ajanta Pharma. The 6M support floor is at ₹2981.46, which is 11.05% below today’s price, indicating solid support. Resistance was at ₹3115.16, which the stock has now broken above by 7.07%. The 50-DMA at ₹3013.6 is above the 200-DMA at ₹2777.1, signaling a bullish trend. The stock is currently trading in the upper third of its 52W range, suggesting that much of the recent move may already be priced in, though the breakout indicates potential for further upside.

Fundamentals & business context

With a PE of 37.7, Ajanta Pharma’s valuation appears stretched given its profit margin of 19.4% and revenue CAGR of 13.4%. However, the profit CAGR of 21.6% suggests that the market may be pricing in future growth. The 21.7% institutional ownership indicates a positive view from smart money, though the low dividend yield of 1.76% may be a concern for income-focused investors. There was no specific NSE catalyst today, but the breakout and strong technicals may be reflecting underlying fundamental strength.

Algorithmic scorecard

The overall scorecard reflects a balanced yet strong position for Ajanta Pharma. The strongest signals include the revenue CAGR of 13.4% and profit CAGR of 21.6%, indicating solid growth trajectory. Additionally, the very low debt level with a D/E of 0.00 showcases excellent financial health. On the weaker side, the low dividend yield of 1.76% may be a drawback for income-seeking investors, and the PEG ratio of 1.75, while reasonable, suggests that the stock is not significantly undervalued. These factors together paint a picture of a growth-oriented company with strong financials but limited income generation through dividends.

Get all details on AJANTPHARM — P&L, peers, shareholding and more on TradeAlone.